Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of AZD6738 Plus Durvalumab in Refractory Biliary Tract Cancer in Patients Who Have Failed Immunotherapy

NCT04298008 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT04298008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04298008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of AZD6738 Plus Durvalumab in Refractory Biliary Tract Cancer in Patients Who Have Failed Immunotherapy
Lead sponsor
Seoul National University Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
June 25, 2020
Completion date
December 31, 2025
Enrollment
26 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bile duct cancer, chemotherapy effect